Talactoferrin alfa clinical trials
Also written Talactoferrin.
How each study uses talactoferrin alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2008 | 3 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 3
Agennix (6) · National Cancer Institute (NCI) (1) · Stanford University (1) · Johns Hopkins University (1)
Studies
Open first, then newest update. How each study uses talactoferrin alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Effect of Talactoferrin in Adults With Non-Small Cell Lung CancerCompletedPhase 1National Cancer Institute (NCI)NCT00923741Written as Talactoferrin
- Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck CancerTerminatedPhase 1Stanford UniversityNCT01528137Written as talactoferrin
- Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung CancerCompletedPhase 3AgennixNCT00707304Written as Talactoferrin
- Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung CancerStatus unknownPhase 3AgennixNCT00706862Written as Talactoferrin
- Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm InfantsStatus unknownPhase 1/2AgennixNCT00854633Written as Talactoferrin
- Safety and Efficacy of Talactoferrin Alfa in Patients With Severe SepsisSuspendedPhase 2/3AgennixNCT01273779Written as Talactoferrin alfa
- Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe SepsisCompletedPhase 2AgennixNCT00630656Written as Talactoferrin alfa
- Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell CarcinomaCompletedPhase 2AgennixNCT00095186Written as Recombinant Human Lactoferrin
- Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.Status unknownNot applicableJohns Hopkins UniversityNCT00377078Written as recombinant human lactoferrin
Codes
What other systems call talactoferrin alfa · ClinicalTrials.gg INT005000
- MeSH (NLM) C515276talactoferrin alfaConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7A055A9QRRTALACTOFERRIN ALFAConfirmed FDA, NLM
- RxNorm 1425932One source FDA
- NCI Thesaurus C78460Talactoferrin AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C515276 | talactoferrin alfa | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7A055A9QRR | TALACTOFERRIN ALFA | Confirmed FDA, NLM |
| RxNorm | 1425932 | — | One source FDA |
| NCI Thesaurus | C78460 | Talactoferrin Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.